ALVOTECH news, videos and press releases
For more news please use our advanced search feature.
ALVOTECH - More news...
ALVOTECH - More news...
- Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
- Alvotech and STADA add to strategic alliance through denosumab partnership
- Alvotech Announces Strategic Refinancing Agreement
- Alvotech Announces Strategic Refinancing Agreement
- Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
- Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
- Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
- Alvotech S.A. Annual General Meeting to be held June 7, 2024
- Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
- Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
- Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
- Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
- Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
- Alvotech Announces Increase in Number of Own Shares
- Alvotech Announces Increase in Number of Own Shares
- Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
